A novel acetylcholinesterase inhibitor, Ro 46-5934, which interacts with muscarinic M2 receptors.
Borroni
E
E
Pharma Division, Preclinical Research, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Damsma
G
G
Giovacchini
C
C
Mutel
V
V
Jakob-Rötne
R
R
Da Prada
M
M
D000109:Acetylcholine / Q000378:metabolism; D000544:Alzheimer Disease / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D000818:Animals; D002219:Carbamates / Q000494:pharmacology*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D005110:Extracellular Space / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D018727:Muscarinic Antagonists; D010830:Physostigmine / Q000494:pharmacology; D051381:Rats; D011976:Receptors, Muscarinic / Q000187:drug effects* / Q000378:metabolism; D012601:Scopolamine / Q000494:pharmacology
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D007211:Indoles; D018727:Muscarinic Antagonists; D011976:Receptors, Muscarinic; C091485:Ro 46-5934; D010830:Physostigmine; D012601:Scopolamine; D000109:Acetylcholine